Interleukin-10, commonly called IL-10, is a small signaling protein (a cytokine) released by immune cells to dial down inflammation. It acts as the immune system’s built-in brake, preventing the body’s defensive responses from spiraling out of control and damaging healthy tissue. But describing IL-10 as simply “anti-inflammatory” undersells the complexity: it also helps activate certain killer T cells, influences wound healing, plays a role in pregnancy, and can be exploited by viruses and tumors to dodge immune detection. That tension between protection and vulnerability makes IL-10 one of the most intensively studied cytokines in immunology and a growing target for new therapies.
How IL-10 Works Inside the Cell
Nearly every type of immune cell can produce IL-10, but the heaviest hitters are a subset of helper T cells, regulatory T cells, macrophages, and certain B cells. Once released, IL-10 binds to a two-part receptor on the surface of nearby cells. That receptor is built from two different protein subunits, IL-10R1 and IL-10R2, which come together to form a four-piece complex on the cell membrane.1PubMed Central. The molecular basis of IL-10 function: from receptor structure to the onset of signaling When IL-10 locks in, it triggers an enzyme called JAK1 inside the cell, which in turn activates a signaling molecule called STAT3. STAT3 is the workhorse behind most of IL-10’s anti-inflammatory effects: it enters the cell nucleus and switches on genes that suppress inflammation while switching off genes that would amplify it.2PubMed Central. Essential role of IL-10/STAT3 in chronic stress-induced immune suppression This signaling chain is remarkably ancient and conserved. Studies comparing IL-10 across species from fish to mammals have found that its anti-inflammatory and regulatory activities are strikingly similar throughout vertebrate evolution.3PubMed. IL10, A Tale of an Evolutionarily Conserved Cytokine across Vertebrates
Shutting Down the Alarm
The most well-characterized job of IL-10 is suppressing antigen presentation, the process by which immune cells display fragments of invaders on their surfaces to recruit reinforcements. IL-10 interferes with this process in several ways: it blocks the activation of dendritic cells and macrophages, reduces their surface display of the molecules T cells need to recognize, and directly turns on genes that quiet immune-cell function.4PubMed Central. Suppression of antigen presentation by IL-10 In macrophages specifically, IL-10 ramps up production of a protein called MARCH-I, which tags surface molecules for destruction. The result is that macrophages pull their alarm signals off the surface, making them much less effective at rallying T cells.5PubMed Central. Interleukin 10 (IL-10)-mediated Immunosuppression: MARCH-I INDUCTION REGULATES ANTIGEN PRESENTATION BY MACROPHAGES BUT NOT DENDRITIC CELLS
This shutdown is normally beneficial. Without it, the inflammatory response triggered by an infection or injury would keep escalating, causing collateral tissue damage far worse than the original threat. But the same braking mechanism creates vulnerabilities that pathogens and tumors learn to exploit.
What Happens When IL-10 Signaling Breaks Down
The clearest illustration of IL-10’s importance comes from rare genetic mutations that disable its receptor. In a landmark study, researchers identified children with early-onset inflammatory bowel disease who carried mutations in the genes encoding IL-10R1 or IL-10R2. Their cells could not respond to IL-10 at all: STAT3 failed to activate, and their immune cells poured out inflammatory signals unchecked.6PubMed Central. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor The clinical picture in these children is severe. A survey of Chinese patients with IL-10 receptor mutations found that nearly 90% presented with diarrhea within the first days of life. Many also developed perianal abscesses, fistulas, oral ulcers, and eczema, with growth significantly below normal. Various treatments were tried, but only bone marrow transplant, which replaces the defective immune system entirely, proved effective.7PubMed. Mutations in Interleukin-10 Receptor and Clinical Phenotypes in Patients with Very Early Onset Inflammatory Bowel Disease: A Chinese VEO-IBD Collaboration Group Survey
These extreme cases illustrate a broader principle: the gut, which is constantly exposed to trillions of microbes, depends on IL-10 more than almost any other tissue to keep the peace between its immune cells and the microbial residents that help with digestion. Without adequate IL-10 signaling, the intestinal lining becomes a battlefield.
IL-10 in the Brain
Microglia, the brain’s resident immune cells, also produce and respond to IL-10. When the brain detects infection or injury, microglia activate and release inflammatory molecules. IL-10 serves as the counterweight, steering microglia away from an aggressive, pro-inflammatory state and toward a calmer phenotype that cleans up debris without causing excessive damage.8PubMed Central. Balancing the immune response in the brain: IL-10 and its regulation When IL-10 is absent, microglia tend to adopt a more destructive profile.9Frontiers in Cellular Neuroscience. Loss of IL-10 Promotes Differentiation of Microglia to a M1 Phenotype
This has caught the attention of Parkinson’s disease researchers. In a mouse model, delivering IL-10 specifically to microglia in the brain region where dopamine-producing neurons die reduced neuron loss, shifted microglia into a state with enhanced debris-clearing ability, and lowered the burden of toxic protein clumps. The approach also suppressed the infiltration of damaging lymphocytes into brain tissue.10PubMed. Microglia-specific IL-10 gene delivery inhibits neuroinflammation and neurodegeneration in a mouse model of Parkinson’s disease The work is preclinical, but it suggests that precisely targeted IL-10 delivery could become a strategy for neurodegenerative diseases driven by chronic brain inflammation.
The Double Edge in Sepsis and Critical Illness
Sepsis provides a dramatic example of IL-10’s dual personality. In the early hours of overwhelming infection, a surge of IL-10 can help rein in the cytokine storm that damages organs. But if IL-10 levels stay high too long or rise at the wrong moment, the immune system becomes paralyzed. Antigen-presenting cells lose their ability to rally defenses against the original pathogen or any secondary infections that arrive. This state, sometimes called immunoparalysis, is associated with worse outcomes including secondary infections and higher mortality.11PubMed Central. The Dual Role of Interleukin-10 in Sepsis: Research Progress and Therapeutic Prospects Clinicians tracking IL-10 levels in critically ill patients are effectively watching the balance between controlled calming and dangerous over-suppression.
A similar pattern shows up in other acute conditions. In traumatic brain injury, blood levels of IL-10 measured on the first day after injury correlate with injury severity, mirroring the pattern seen with the pro-inflammatory cytokine IL-6. Higher levels of both on day one predict more serious brain damage on imaging.12PubMed Central. Inflammation biomarkers IL‑6 and IL‑10 may improve the diagnostic and prognostic accuracy of currently authorized traumatic brain injury tools During COVID-19, a meta-analysis found that circulating IL-10 was significantly higher in patients with severe disease and higher still in those who did not survive, making it a potential prognostic marker alongside IL-6.13PubMed Central. Circulating Levels of Interleukin-6 and Interleukin-10, But Not Tumor Necrosis Factor-Alpha, as Potential Biomarkers of Severity and Mortality for COVID-19: Systematic Review with Meta-analysis
How Viruses Hijack IL-10
Certain viruses have independently evolved their own versions of IL-10. Human cytomegalovirus (HCMV) is perhaps the best-known example: it encodes viral IL-10 proteins that can bind the host’s IL-10 receptor and trigger some of the same downstream effects, including suppressing MHC class II molecules on cell surfaces. This essentially blindfolds the immune system, making it harder for T cells to detect and kill infected cells.14PubMed Central. Human Cytomegalovirus Interleukin 10 Homologs: Facing the Immune System Other herpes viruses carry similar IL-10 look-alikes. The fact that multiple virus families have independently converged on this strategy underscores how powerful the IL-10 pathway is at suppressing immune responses.
Even without producing their own version, persistent viruses benefit from the host’s own IL-10. In mouse models of chronic viral infection, blocking the IL-10 receptor converted a long-lasting, smoldering infection into one the immune system rapidly cleared, while also preventing the functional exhaustion of memory T cells that normally characterizes chronic infection.15PubMed. IL-10, T cell exhaustion and viral persistence A related study showed that IL-10 and another checkpoint molecule, PD-L1, suppress T cells through separate pathways during persistent infection, and blocking either one reduces viral levels.16PubMed Central. IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection This finding foreshadowed the explosion of interest in immune checkpoint blockade that now dominates cancer immunotherapy.
The IL-10 Paradox in Cancer
IL-10’s role in tumors is genuinely paradoxical, and the field has gone back and forth on whether it is friend or foe. On one hand, tumors and the immune cells surrounding them often produce large amounts of IL-10. Within the tumor microenvironment, IL-10 suppresses antigen presentation, dampens helper T cell responses, and promotes the development of regulatory T cells that tolerate the tumor rather than attacking it.17PubMed Central. Tumor promoting roles of IL-10, TGF-β, IL-4, and IL-35: Its implications in cancer immunotherapy It also directly inhibits the display of recognition molecules on antigen-presenting cells, helping tumors evade detection.18PubMed. Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy
On the other hand, IL-10 appears essential for expanding and arming the very CD8+ killer T cells the immune system needs to destroy tumors. Mice and humans lacking IL-10 develop spontaneous cancers more readily, suggesting that without IL-10’s support of killer T cell function, tumor surveillance fails.19PubMed Central. Immune regulation and cytotoxic T cell activation of IL-10 agonists – Preclinical and clinical experience This paradox has led to two opposing therapeutic strategies: giving patients more IL-10 to boost killer T cells, and blocking IL-10 to unmask tumors to immune surveillance. Both have shown promise in different contexts.
Therapeutic Approaches That Add IL-10
The most advanced effort to harness IL-10 against cancer is pegilodecakin, a modified form of IL-10 attached to polyethylene glycol to extend its life in the bloodstream. In cancer patients, pegilodecakin activated CD8+ T cells systemically, expanding new T cell populations that were undetectable before treatment to become 1–10% of the total circulating T cell pool. It also boosted production of interferon-gamma and granzyme B, molecules these T cells use to kill tumor cells.20PubMed Central. PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients
In a Phase 1 study of patients with advanced kidney cancer who had already failed prior treatments, pegilodecakin combined with checkpoint inhibitors produced encouraging results: the combination with anti-PD-1 drugs yielded a response rate of about 43%, with a median progression-free survival of roughly 14 months. Pegilodecakin alone was much less effective, though it still showed manageable side effects including anemia and low platelet counts.21PubMed Central. Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study The combination approach makes biological sense: pegilodecakin energizes T cells, while checkpoint inhibitors remove the PD-1 brake that tumors use to shut those T cells down.
Therapeutic Approaches That Block IL-10
The opposite strategy, temporarily blocking IL-10 signaling, has shown value in preclinical settings. In animal models, blocking the IL-10 pathway at the time of vaccination enhanced the immune response enough to clear chronic viral infections and slow tumor growth.22PubMed. Manipulating IL-10 signalling blockade for better immunotherapy Timing turns out to be critical. A brief, well-timed blockade of IL-10 can amplify the wave of killer T cells generated by a vaccine, while chronic blockade might unleash autoimmune damage or remove the brake on inflammation where it is genuinely needed.23PubMed Central. Targeting interleukin-10 signalling for cancer immunotherapy, a promising and complicated task Moving this approach into human trials remains complicated because the line between “helpful boost” and “dangerous unleashing” is context-dependent and hard to predict.
Engineered Bacteria for Gut Delivery
One of the more creative IL-10 delivery strategies involves engineering food-grade bacteria to secrete it directly in the gut. The concept is appealing for inflammatory bowel disease: rather than flooding the whole body with IL-10 through an injection, you send the molecule exactly where it is needed. An engineered strain of Lactococcus lactis, a bacterium commonly used in cheese and yogurt production, has been modified to secrete IL-10 during its passage through the intestines. In mouse studies, oral delivery of these bacteria significantly reduced measures of intestinal inflammation, improved gut barrier integrity, and dampened immune activation locally.24PubMed Central. Effects in the use of a genetically engineered strain of Lactococcus lactis delivering in situ IL-10 as a therapy to treat low-grade colon inflammation
Other groups have experimented with different microbial chassis, including E. coli Nissle 1917, a probiotic strain, and the yeast Saccharomyces boulardii. Getting the bacteria to secrete enough biologically active IL-10 has been a technical challenge. Some transport systems yielded too little protein, while others produced protein that was structurally correct but biologically inactive. The yeast-based system proved more successful at secreting functional protein.25PubMed Central. Improving health from the inside: Use of engineered intestinal microorganisms as in situ cytokine delivery system The broader field of engineered probiotics is advancing rapidly, with newer platforms incorporating features like acid-resistant coatings for surviving stomach transit, targeted colonization of inflamed sites, and smart biosensors that release therapeutic molecules in response to local inflammatory signals.26PubMed Central. Engineered probiotics: a new era in treating inflammatory bowel disease
IL-10 in Wound Healing and Scar Prevention
Fetuses heal wounds without scarring, and IL-10 appears to be a major reason why. Fetal skin produces high levels of IL-10 during the repair process, while adult skin does not. Experimental overexpression of IL-10 in adult wound models has been shown to recapitulate fetal-like healing, resulting in tissue that looks and functions more like the original rather than producing thick scar tissue.27PubMed Central. Regenerative Wound Healing: The Role of Interleukin-10 The mechanism involves more than just calming inflammation. IL-10 activates STAT3 signaling in fibroblasts, the cells that lay down new structural material during repair, prompting them to produce a matrix rich in hyaluronan. This type of matrix resembles what fetal tissue uses during regeneration, and it supports repair that restores normal tissue architecture rather than laying down dense scar collagen.28PubMed Central. Interleukin-10-mediated regenerative postnatal tissue repair is dependent on regulation of hyaluronan metabolism via fibroblast-specific STAT3 signaling This has obvious implications for surgical wounds, burn injuries, and conditions like pulmonary or liver fibrosis, where excessive scarring is the core problem.
IL-10 and Pregnancy
A developing fetus is, immunologically speaking, half foreign. The mother’s immune system must tolerate the presence of paternal antigens without mounting a rejection response, and IL-10 is one of the key molecules maintaining that truce. Both maternal and fetal cells secrete IL-10 at the interface where the placenta meets the uterine wall.29PubMed Central. Interleukin-10: a multi-faceted agent of pregnancy Beyond immune tolerance, IL-10 also protects against vascular dysfunction during pregnancy, which is relevant to conditions like preeclampsia. Research suggests that boosting IL-10 levels could serve as a therapeutic strategy for adverse pregnancy outcomes, though clinical applications are still being explored.30PubMed Central. Interleukin-10: a pleiotropic regulator in pregnancy
The Metabolic Connection
IL-10 shows up in an unexpected place: fat tissue. In human white adipose tissue, IL-10 expression and secretion correlate positively with body mass index and with measures of insulin resistance. The primary producers turn out to be pro-inflammatory macrophages that infiltrate fat tissue as it expands. In human fat-tissue macrophages and immune cells, IL-10 pushes them toward a less inflammatory profile, likely serving as a local feedback mechanism to limit the damage caused by obesity-driven inflammation.31PubMed. Human-Specific Function of IL-10 in Adipose Tissue Linked to Insulin Resistance Interestingly, the same study found that IL-10 had no direct effect on fat cell behavior in humans, despite earlier mouse studies suggesting otherwise. This species difference is a useful reminder that mouse immunology does not always translate directly.
Separately, a line of B cells that produce IL-10 in the abdominal fat tissue has been linked to protection against age-related insulin resistance. When these IL-10-producing B cells were knocked out in mice, aging-related inflammation and insulin resistance worsened, and lifespan shortened. Transferring IL-10-producing B cells from normal mice partially reversed the damage.32PubMed Central. Interleukin-10 expressing B lineage cells in visceral adipose tissue protect against aging-related insulin resistance and extend lifespan The implication is that IL-10 is not just a bystander in metabolic disease but an active player in determining how gracefully the immune and metabolic systems age together.
Why IL-10 Is Hard to Work With as a Drug
Given how many diseases involve inflammation, you might wonder why IL-10-based therapies have not already become mainstream. The answer lies in the cytokine’s frustrating context-dependence. The same molecule that protects gut tissue and promotes scar-free healing also enables chronic infections and helps tumors hide. Systemic injection of IL-10 can cause unwanted immune suppression far from the target site, while blocking it risks triggering autoimmune flares or losing the regulatory feedback loops that keep inflammation in check after infections clear.
This is why the most promising newer approaches focus on precision: delivering IL-10 to specific cells using viral vectors that only activate in microglia, engineering gut bacteria that release it locally in the colon, or combining it with checkpoint inhibitors so its T cell-boosting effects are amplified while a second drug handles the suppressive side. The era of simply giving or blocking IL-10 systemically appears to be giving way to strategies that respect the cytokine’s context-dependent personality, delivering the right amount, in the right place, at the right time.